Bristol-Myers Squibb (NYSE:BMY) is scheduled to announce its Q4 earnings on January 24. We expect the company to post steady top line and bottom line growth led by its oncology and cardiovascular drugs - Opdivo and Eliquis. These two drugs combined accounted for close to 60% of the company's over...
Bristol-Myers Squibb (NYSE:BMY) is scheduled to announce its Q4 earnings on January 24. We expect the company to post steady top line and bottom line growth led by its oncology and cardiovascular drugs - Opdivo and Eliquis. These two drugs combined accounted for close to 60% of the company's over...
Share this Article
Recommended